Annovis Bio Narrows Loss in Q2
Annovis Bio (NYSE:ANVS), a biotechnology company focused on innovative treatments for neurodegenerative diseases, released its earnings results for the second quarter on August 12, 2025. The company reported a net loss per share of $(0.32) (GAAP), which was $0.08 better than analyst expectations of $(0.40) (GAAP). No revenue was reported, matching estimates, as Annovis remains in a pre-commercial stage. The quarter featured ongoing cost discipline, an improved cash position as of June 30, 2025 compared to December 31, 2024, and continuing clinical progress with its lead drug candidate, buntanetap. Overall, the period revealed steady operational management during a critical stage for the business.
Source: Analyst estimates for the quarter provided by FactSet.
Annovis Bio develops therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s primary asset, buntanetap, aims to block the production of several toxic brain proteins involved in these diseases. This multi-target approach is designed to address the complex biological processes behind AD and PD, going beyond the single-protein focus of many competing drugs.
Source Fool.com
